The expanding incretin universe: from basic biology to clinical translation

Drucker, Daniel J., Holst, Jens J.·2023·Diabetologia
DOI 10.1007/s00125-023-05906-7

Cited by (243)

Items 201–243 of 243

  1. How do we balance metabolic surgery and emerging incretin-based medical therapies for type 2 diabetes?
    Hamayle Saeed, Mary‐Elizabeth Patti · 2025 · Expert Review of Endocrinology & Metabolism
  2. Novel Peptides as GIPR/GLP-1R/GCGR Triagonists for Treating Type 2 Diabetes Mellitus
    Qi-Long Hu, Steven H. Liang · 2025 · ACS Medicinal Chemistry Letters
  3. The Hypothalamus-Pituitary in Males in Health and Disease
    Stephen J. Winters · 2025 · Springer eBooks
  4. Glycaemic and bodyweight effects of GIPR coding variation reflect differences in both surface expression and intrinsic functional impairment
    Yusman Manchanda, Rofaida Desoki, Eugene J. Gardner, John R. B. Perry, David B. Wainscott, Cynthia Stutsman, Claudia Langenberg, Matthew P. Coghlan, Pallav Bhatnagar, Joseph D. Ho et al. · 2025 · medRxiv
  5. A tablespoon of mayonnaise modulates the glycemic response to rice
    Naoki Kawada, Naoki Fujiwara, Ryosuke Matsuoka, Kazunori Utsunomiya · 2025 · Bioscience Biotechnology and Biochemistry
  6. Metabolic sexual dimorphism in hypothalamic Fezf1 neuron-specific BDNF knockout
    Dayana Cabral da Silva, Ariane Maria Zanesco, Fernando Valdivieso Rivera, Ana Luisa Gallo-Ferraz, Marcela Reymond Simoes, Bruna Bombassaro, Carlos H. Sponton, Licio Augusto Velloso · 2025 · Biology of Sex Differences
  7. Differential Features of Cholecystokinin-Releasing Peptides Derived from Food Proteins: Peptide Length, Amino Acid Composition and Primary Structure; Analysis of Currently Identified Peptide Sequences
    Giovanni Tulipano · 2025 · International Journal of Molecular Sciences
  8. Anti-GIP Antibodies and Future Diabetes Risk: Eight-Year Prospective Cohort Study
    Takahide Hahimoto, Naoki Ohtake, Tokiko Okamoto, Bo‐Shi Zhang, Yoich Yoshida, Hirotaka Takizawa, Masaya Yamaga, Tomohiko Yoshida, Takeshi Yagihashi, Rikako Furukawa et al. · 2025 · Research Square
  9. Research Progress on Intervention for Type 2 Diabetes by Activating Endogenous GLP-1 Secretion
    佩玲 管 · 2025 · Advances in Clinical Medicine
  10. RNA binding protein HuD regulates the biosynthesis of glucagon-like peptide 1 in intestinal L-cells
    Sukyoung Han, Myeongwoo Jung, Seungyeon Ryu, Seongho Cha, Hyosun Tak, Seung Min Jeong, Eun Kyung Lee · 2025 · Biochemistry and Biophysics Reports
  11. References
    2025 · American Diabetes Association eBooks
  12. Tirzepatide improves pancreatic β-cell function in mice and patients with type 2 diabetes
    Zhehui Li, Jiacheng Guo, Ying Cheng, Tongyu Zhang, Xiumei Luo, Shuyi Zhang, Qi Ren, Zhiqiang Wu, Ning Chen, Mingyu Li · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  13. Bibliography
    2026 · Elsevier eBooks
  14. Insulin Resistance: Pathophysiology, Molecular Mechanisms, and Genetic Insights
    Hans‐Ulrich Häring, Baptist Gallwitz · 2026 · Elsevier eBooks
  15. Rôle des interactions mitochondrie-réticulum endoplasmique dans le contrôle de la sécrétion du Glucagon-Like Peptide 1 (GLP-1) et altérations au cours du diabète de type 2
    Alexandre Humbert · 2024 · theses.fr (ABES)
  16. Endogenous Incretin Insufficiency in Obesity: Etiological Defect or Metabolic Maladaptation?
    Luís Jesuíno de Oliveira Andrade, Gabriela Correia Matos de Oliveira, Alcina Maria Vinhaes Bittencourt, Osmário Jorge de Mattos Salles, Luís Matos de Oliveira · 2026 · Research Square
  17. Glucagon-like Peptide-1 and Dual GIP/GLP-1 Receptor Agonists in Brain: Exploring the Expanding Role and Safety in Neuropsychiatry
    Ana Cristina Tudosie, Loredana-Maria Marin, Simona Georgiana Popa, Andreea Loredana Golli · 2026 · International Journal of Molecular Sciences
  18. Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy
    Monika Gupta, Jitendra Shukla · 2026 · The Indian Journal of Medical Research
  19. Anti-GIP antibodies and future diabetes related risk: an eight-year prospective cohort study
    Takahide Hashimoto, Naoki Ohtake, Tokiko Okamoto, Bo‐Shi Zhang, Yoich Yoshida, Hirotaka Takizawa, Masaya Yamaga, Tomohiko Yoshida, Amika Kajiyama, Takeshi Yagihashi et al. · 2026 · Frontiers in Endocrinology
  20. A Physiological Model of Incretin‐Based Therapies and Hierarchical Energy Allocation Across Metabolic Phenotypes
    Christine Karolina Stier, Sonja Chiappetta, Mohammad Kermansaravi · 2026 · Diabetes Obesity and Metabolism
  21. Liens entre diabète de type 2 et maladie de Parkinson
    Ambrine Arrar, Saad El Mallem, Magalie A. Ravier, Safia Costes · 2026 · médecine/sciences
  22. Use of second-generation incretin analogs (GLP-1 and GIP receptor agonists) in type 1 diabetes and latent autoimmune diabetes in adults: A systematic review
    Michael Paul Horne, Hannah Pollard, Heather Day, Christina L. Baker · 2026 · Journal of the American Association of Nurse Practitioners
  23. Incretin-based therapies: Effects on plasma lipids and potential mechanisms
    Majid Mufaqam Syed‐Abdul, Gary F. Lewis · 2026 · Pharmacology & Therapeutics
  24. CD59 drives diet-induced obesity and glucose intolerance, insulin resistance, and metabolic dysfunction-associated steatotic liver disease
    Marian Zeibak, Netanel Karbian, Yael Riahi, Saja Baraghithy, Labiba Ahmad, Adi Tabib, Ifat Abromovitz, Bella Agranovitz, Hadar Benyamini, Eyal Gottlieb et al. · 2026 · npj Metabolic Health and Disease
  25. Peptide Marriages: Modular Assembly of Multi‐Agonist Therapeutics
    Kristina A. Kostadinova, Jan L. Venne, Soňa Krajčovičová, James Dodgson, Wouter F. J. Hogendorf, Thomas E. Nielsen, David Hymel, Hannah L. Bolt, Andie Collinson, Jason Day et al. · 2026 · Chemistry - A European Journal
  26. Obese and overweight patients with type 2 diabetes mellitus are not treated optimally - an overview of current clinical practice and future perspectives
    Tanja Miličević, Ivna Cvitković, Špela Volčanšek, Niki Katsiki, Dimitri P. Mikhailidis, Dimitrios Patoulias, Emir M. Muzurović · 2026 · Expert Review of Clinical Pharmacology
  27. Incretins: From Gene Expression to Secretion and Action of GLP-1 and GIP
    Carolina B. Lobato, Jens J. Holst · 2026 · Elsevier eBooks
  28. Rapport 26-08. Les agonistes des récepteurs aux incrétines dans le traitement de l’obésité : entre efficacité clinique, éthique et économie de la santé
    Charles‐Henri Malbert, Jacques Delarue, Jean‐Louis Guéant · 2026 · Bulletin de l Académie Nationale de Médecine
  29. GIP Acutely Blunts Insulin- and GLP-1–Induced Muscle Microvascular Perfusion
    Jia Liu, Changzoon Chun, Thomas K. Sin, Fang Zhao, Kevin W. Aylor, Nusrat Jahan Tushi, Shengyi Sun, Zhenqi Liu · 2026 · Diabetes
  30. The Pleiotropic Therapeutic Perspectives of GLP-1 and GIP Receptor Agonists in Spinal Cord Injury: A Narrative Review
    Shuhao Zhang, Song Liu, Mi Zhou, Jian Wang, Yue Zhang, Hao Zhong, Guangzhi Ning · 2026 · Molecular Neurobiology
  31. Anti-Obesity Medications in Longevity and Aesthetic Medicine
    Julia Bijoch · 2026 · Journal of Clinical Medicine
  32. Non-digestible stachyose reverses overnutrition-induced insulin resistance via stimulating the secretion of glucagon-like peptide-1
    Jiao Wang, Jiushuang Zhu, Chao Zhu, Xinyan Zan, Honghong Zhou, Ying Zhi, Shuang Liu, Jinlin Liu, Min Zhu, Jianwei Wang et al. · 2026 · Food & Function
  33. Glycemic and bodyweight effects of GIPR coding variation reflect differences in surface expression and intrinsic functional impairment
    Yusman Manchanda, Rofaida Desoki, Eugene J. Gardner, John R. B. Perry, David B. Wainscott, Cynthia Stutsman, Claudia Langenberg, Matthew P. Coghlan, Pallav Bhatnagar, Joseph D. Ho et al. · 2026 · Science Advances
  34. Obesity science, research gaps, and opportunities in the new era of obesity medicines: an Endocrine Society scientific statement
    Ania M. Jastreboff, Jamy D. Ard, Kevin D. Hall, Lee M. Kaplan, Harlan M. Krumholz, Michelle Anne Van Name, Donna H. Ryan, Daniel J. Drucker · 2026 · Endocrine Reviews
  35. Cardiovascular effects of incretin receptor agonists: beyond glycemic control
    Marko P. Ravić, Ivan M. Srejovic, Isidora Milosavljević, Jovana N. Novakovic, Vladimir Jakovljević, Ksenija Vučićević, Djurdjina Petrovic, Maja D. Muric · 2026 · Canadian Journal of Physiology and Pharmacology
  36. Fasting gut hormone levels following long-term recovery from Anorexia Nervosa: A cross-sectional study
    Theresa Kolb, Friederike I. Tam, Claudia Förster Ribet, Michaela Ohme, Lina Carlotta Schlolaut, Joseph Adam King, Veit Roessner, Suzanne Lee Dickson, Carmine Maria Pariante, Alessandra Borsini et al. · 2026 · Journal of Eating Disorders
  37. Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists
    Dorota Bartkowiak, Barlomiej Jakubczyk, Adam Lasota, Łukasz Kopoczyński, Michal Wiesner, Lukasz Wodzinski, Kamil Boguszewski, Hubert Porazinski, Agnieszka Mlynarska, Oskar Ratajski · 2026 · Cureus
  38. Incretin signaling suppresses high glucose–induced β-cell hypoxia through a cAMP/PKA-dependent mechanism
    Paksiree Saranaruk, Yoshifumi Sato, Masafumi Tsuruta, Kazuya Yamagata · 2026 · Biochemical and Biophysical Research Communications
  39. Apports des nouveaux traitements du diabète et de l’obésité dans le syndrome d’apnées obstructives du sommeil : vers un changement de paradigme
    Karima Benmohammed, Paul Elie Valensi · 2026 · Médecine des Maladies Métaboliques
  40. Potential Physiological Convergence Between GLP-1 Receptor Signaling and Hepatocyte TAZ in Metabolic Liver Disease: From Metabolic Homeostasis to Fibrotic Remodeling
    Mohammed F. Gholam · 2026 · Cells
  41. Liraglutide reduces lipid accumulation in human orbital fibroblasts in Graves’ orbitopathy
    Chih-Wei Shih, Shyang-Rong Shih, Yi-Hsuan Wei, CHIA-HUNG LIN, Liao Shu-Lang, Ting-An Chou, I Chu, Hou-Jen Chen, Neng-Li Liao, Feng‐Chiao Tsai · 2026 · Frontiers in Endocrinology
  42. No journal is an island
    Hindrik Mulder · 2026 · Diabetologia
  43. Gut-derived glucagon-like peptides attenuate T cell-induced intestinal injury
    Jacqueline A. Koehler, Laurie L. Baggio, Xiemin Cao, Rui Shang, Bernardo Yusta, Chi Kin WONG, Dianne Matthews, Darleen A. Sandoval, Daniel J. Drucker · 2026 · Cell Reports Medicine